टाइटन बायोटेक शेयर की कीमत

Specialty Chemicals company Titan Biotech announced Q4FY26 & FY26 results Consolidated Financial Highlights: Annual Performance (FY26 vs FY25): Revenue from Operations: The company reported a significant YoY increase of 31.80%, with revenue reaching Rs 20,619.03 lakh in FY26 compared to Rs 15,645.08 lakh in FY25. Total Income: Total income for FY26 stood at Rs 21,160.05 lakh, up from Rs 16,036.33 lakh in the previous fiscal year. Profit for the Period: Net profit for the year grew by 38.80% YoY to Rs 2,988.52 lakh in FY26 from Rs 2,153.16 lakh in FY25. Total Comprehensive Income: The consolidated total comprehensive income for FY26 was Rs 2,979.70 lakh compared to Rs 2,160.46 lakh in FY25. Quarterly Performance (Q4FY26 vs Q3FY26 and Q4FY25): Revenue from Operations: Revenue in Q4FY26 was Rs 4,883.35 lakh, representing a YoY growth of 38.85% from Rs 3,516.93 lakh in Q4FY25. However, on a QoQ basis, it declined by 13.58% from Rs 5,650.57 lakh in Q3FY26. Profit for the Period: The profit for Q4FY26 stood at Rs 672.91 lakh, a YoY increase of 66.28% from Rs 404.68 lakh in Q4FY25. On a QoQ basis, profit decreased by 21.10% from Rs 852.86 lakh in Q3FY26. Total Comprehensive Income: For Q4FY26, the company reported a total comprehensive income of Rs 658.61 lakh, up YoY from Rs 398.87 lakh but down QoQ from Rs 854.69 lakh. Standalone Financial Highlights: Annual Performance (FY26 vs FY25): Revenue from Operations: Standalone revenue mirrored the consolidated figure at Rs 20,619.03 lakh for FY26, a 31.80% increase over FY25's Rs 15,645.08 lakh. Profit for the Period: Standalone net profit showed robust YoY growth of 50.22%, rising to Rs 2,744.72 lakh in FY26 from Rs 1,827.11 lakh in FY25. Total Comprehensive Income: Standalone total comprehensive income for FY26 was Rs 2,736.07 lakh compared to Rs 1,834.41 lakh in FY25. Quarterly Performance (Q4FY26 vs Q3FY26 and Q4FY25): Revenue from Operations: Q4FY26 standalone revenue was Rs 4,883.35 lakh, increasing 38.85% YoY from Rs 3,516.93 lakh but decreasing 13.58% QoQ from Rs 5,650.57 lakh. Profit for the Period: Standalone profit for Q4FY26 was Rs 655.57 lakh, a 74.07% YoY increase from Rs 376.61 lakh and a 16.68% QoQ decrease from Rs 786.82 lakh. Business Highlights: Dividend Recommendation: The Board of Directors has recommended a dividend of Rs 0.50 (Fifty Paisa Only) per equity share for the financial year ended March 31, 2026, subject to shareholder approval. Segment Performance: The company operates in only one reportable business segment. Equity Share Subdivision: The subdivision of Equity Shares was made effective from February 20, 2026, changing the face value from Rs 10 per share to Rs 2 per share. Consequently, the paid-up share capital consists of 4,13,18,500 Equity Shares of Rs 2 each. Associate Entities: The consolidated results include the share of profit/loss from associate companies Peptech Biosciences Limited and Titan Media Limited. Audit Opinion: The Statutory Auditors have issued an unmodified opinion on the standalone and consolidated financial results for the quarter and year ended March 31, 2026. Re-appointment of Cost Auditor: The Board approved the re-appointment of M/s Sanjay Kumar Garg & Associates, Cost Accountants, as the Cost Auditor for the financial year 2026-2027. Result PDF

• ट्रेंडलाइन
• 1 सप्ताह 2 दिन पहले

स्पेशलिटी केमिकल्स कंपनी टाइटन बायोटेक ने Q3FY26 परिणामों की घोषणा की ऑपरेशन: Q3FY25 के दौरान रु. 3,827.58 लाख के मुकाबले रु. 5,650.57 लाख, बदलाव 48%. पीबीटी: Q3FY25 के दौरान रु. 510.49 लाख के बदले रु. 1,056.21 लाख, 107% बदलें. पीएटी: Q3FY25 के दौरान रु. 439.01 लाख पर रु. 852.86 लाख, 94% बदलें. ईपीएस: Q3FY26 के लिए रु. 10.32. परिणाम PDF

• ट्रेंडलाइन
• 4 महीने पहले